+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional, Observational, Expanded Access), by Indication and Segment Forecasts, 2020 - 2027

  • ID: 4396385
  • Report
  • May 2020
  • Region: Global
  • 120 pages
  • Grand View Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Charles River Laboratory
  • Clinipace
  • Eli Lilly and Company
  • ICON Plc
  • IQVIA
  • Novo Nordisk A/S
  • MORE
Clinical Trials Market Growth & Trends

The global clinical trials market size is expected to reach USD 69.9 billion by 2027. It is projected to exhibit a CAGR of 5.1% during the forecast period. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals as well as small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease trial costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 (coronavirus) and the increasing demand for developing a suitable treatment for the same is driving the market growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288 therapeutics and 106 vaccines in development. Out of this, nearly 7.0% therapeutics are in Phase IV, 21.0% in Phase III, 43.0% & 13.0% in Phase II & Phase I respectively.

The pandemic has also resulted in global disruption of traditional onsite clinical trials. Hence, the regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the World Health Organization (WHO) to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device & drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights
  • Phase III clinical trials dominated the market with a revenue share of 53.0% in 2019. This is attributed to the complexity level associated with this phase
  • Interventional design segment accounted for the largest market share of 45.6% in 2019 in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers
  • North America held 51.2% of market share in 2019. Favorable government initiatives and the presence of large numbers of players in U.S. offerings advanced services are responsible for the growth
  • Asia Pacific is expected to expand at the fastest CAGR of 6.1% over the forecast period owing to the increasing patient pool and cost efficient services

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Charles River Laboratory
  • Clinipace
  • Eli Lilly and Company
  • ICON Plc
  • IQVIA
  • Novo Nordisk A/S
  • MORE
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1: Understanding the market dynamics
1.9.2. Objective 2: Understanding the market estimates and forecasts
1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.3.1. Therapeutics in development
3.3.2. Vaccines in development
3.4. Fast track of clinical trials
3.4.1. FDA initiative –CTPA
3.4.2. UK initiative –ACCORD
3.4.3. ASIA Pacific initiative - DCGI
3.4.4. University of Pittsburgh School of Medicine-UPMC
3.5. Solidarity clinical trials
3.5.1. Participation in solidarity trials
3.5.2. Solidarity clinical trial for vaccines
3.6. Virtual clinical trials
3.6.1. In-home clinical services
3.7. COVID-19 impact on clinical trials
3.7.1. Companies with phase 1 trial disruption
3.7.2. Companies with phase 2 trial disruption
3.7.3. Companies with phase 3 trial disruption
3.8. Market Dynamics
3.8.1. Market Driver Analysis
3.8.1.1. Increasing research and development promoting outsourcing
3.8.1.2. Adoption of new technology in clinical research
3.8.1.3. Increasing prevalence of chronic disease
3.8.1.4. Globalization of clinical trials
3.8.2. Market Restraint Analysis
3.8.2.1. Stringent regulatory policies for patient enrollment
3.8.2.2. Lack of skilled workforce in clinical research
3.8.3. Industry Challenges
3.8.3.1. Rising cost of clinical trial
3.9. Clinical Trials: Market Analysis Tools
3.9.1. Industry Analysis – Porter’s
3.9.1.1. Supplier Power
3.9.1.2. Buyer Power
3.9.1.3. Substitution Threat
3.9.1.4. Threat from new entrant
3.9.1.5. Competitive rivalry
3.9.2. PESTEL Analysis
3.9.2.1. Political Landscape
3.9.2.2. Environmental Landscape
3.9.2.3. Social Landscape
3.9.2.4. Technology Landscape
3.9.2.5. Legal Landscape
3.9.3. Major Deals & Strategic Alliances Analysis

Chapter 4. Clinical Trials Market: Segment Analysis, by Phase, 2016 - 2027 (USD Million)
4.1. Definitions & Scope
4.2. Phase market share analysis, 2019 & 2027
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027for the following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV

Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 - 2027 (USD Million)
5.1. Definitions & Scope
5.2. Study Design market share analysis, 2019 & 2027
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, By Study Design, 2016 to 2027
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded Access

Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 - 2027 (USD Million)
6.1. Definitions & Scope
6.2. Indication market share analysis, 2019 & 2027
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, By Indication, 2016 to 2027
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
6.5.1. Autoimmune/inflammation
6.5.2. Pain management
6.5.3. Oncology
6.5.4. CNS condition
6.5.5. Diabetes
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others

Chapter 7. Clinical Trials Market: Regional Market Analysis, by Phase, 2016 - 2027 (USD Million)
7.1. Definitions & Scope
7.2. Regional Market Share Analysis, 2019 & 2027
7.3. Regional Market Dashboard
7.4. Regional Market Snapshot
7.5. Regional Market Share, 2019
7.6. Market Size, & Forecasts, and Trend Analysis, 2016 to 2027:
7.7. North America
7.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.7.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.7.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.7.4. Market estimates and forecast, By Indication, 2016 - 2027 (USD Million)
7.7.5. U.S.
7.7.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.7.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.7.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.7.6. Canada
7.7.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.7.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.7.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.8. Europe
7.8.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.8.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.8.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.8.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.8.5. Germany
7.8.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.8.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.8.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.8.6. UK
7.8.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.8.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.8.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.8.7. France
7.8.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.8.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.8.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.8.8. Italy
7.8.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.8.8.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.8.8.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.8.9. Spain
7.8.9.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.8.9.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.8.9.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.9. Asia Pacific
7.9.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.9.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.9.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.9.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.9.5. China
7.9.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.9.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.9.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.9.6. Japan
7.9.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.9.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.9.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.9.7. India
7.9.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.9.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.9.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.9.8. Australia
7.9.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.9.8.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.9.8.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.9.9. South Korea
7.9.9.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.9.9.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.9.9.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.10. Latin America
7.10.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.10.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.10.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.10.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.10.5. Brazil
7.10.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.10.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.10.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.10.6. Mexico
7.10.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.10.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.10.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.10.7. Argentina
7.10.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.10.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.10.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.10.8. Colombia
7.10.8.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.10.8.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.10.8.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.11. Middle East and Africa
7.11.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.11.2. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.11.3. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.11.4. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.11.5. South Africa
7.11.5.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.11.5.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.11.5.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.11.6. Saudi Arabia
7.11.6.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.11.6.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.11.6.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)
7.11.7. UAE
7.11.7.1. Market estimates and forecast, by phase, 2016 - 2027 (USD Million)
7.11.7.2. Market estimates and forecast, by study design, 2016 - 2027 (USD Million)
7.11.7.3. Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

Chapter 8. Clinical Trials Market– Competitive Analysis
8.1. Key companies profiled
8.1.1. IQVIA
8.1.1.1. Company Overview
8.1.1.2. Financial Performance
8.1.1.3. Product Benchmarking
8.1.1.4. Strategic Initiatives
8.1.2. PAREXEL International Corporation
8.1.2.1. Company Overview
8.1.2.2. Financial Performance
8.1.2.3. Product Benchmarking
8.1.2.4. Strategic Initiatives
8.1.3. Pharmaceutical Product Development, LLC
8.1.3.1. Company Overview
8.1.3.2. Financial Performance
8.1.3.3. Product Benchmarking
8.1.3.4. Strategic Initiatives
8.1.4. Charles River Laboratory
8.1.4.1. Company Overview
8.1.4.2. Financial Performance
8.1.4.3. Product Benchmarking
8.1.4.4. Strategic Initiatives
8.1.5. ICON Plc
8.1.5.1. Company Overview
8.1.5.2. Financial Performance
8.1.5.3. Product Benchmarking
8.1.5.4. Strategic Initiatives
8.1.6. Wuxi AppTec Inc
8.1.6.1. Company Overview
8.1.6.2. Financial Performance
8.1.6.3. Product Benchmarking
8.1.6.4. Strategic Initiatives
8.1.7. PRA Health Sciences
8.1.7.1. Company Overview
8.1.7.2. Financial Performance
8.1.7.3. Product Benchmarking
8.1.7.4. Strategic Initiatives
8.1.8. SGS SA
8.1.8.1. Company Overview
8.1.8.2. Financial Performance
8.1.8.3. Product Benchmarking
8.1.8.4. Strategic Initiatives
8.1.9. Syneos Health
8.1.9.1. Company Overview
8.1.9.2. Financial Performance
8.1.9.3. Product Benchmarking
8.1.9.4. Strategic Initiatives
8.1.10. Chiltern International Ltd
8.1.10.1. Company Overview
8.1.10.2. Financial Performance
8.1.10.3. Product Benchmarking
8.1.10.4. Strategic Initiatives
8.1.11. Eli Lilly and Company
8.1.11.1. Company Overview
8.1.11.2. Financial Performance
8.1.11.3. Product Benchmarking
8.1.11.4. Strategic Initiatives
8.1.12. Novo Nordisk A/S
8.1.12.1. Company Overview
8.1.12.2. Financial Performance
8.1.12.3. Product Benchmarking
8.1.12.4. Strategic Initiatives
8.1.13. Pfizer
8.1.13.1. Company Overview
8.1.13.2. Financial Performance
8.1.13.3. Product Benchmarking
8.1.13.4. Strategic Initiatives
8.1.14. Clinipace
8.1.14.1. Company Overview
8.1.14.2. Financial Performance
8.1.14.3. Product Benchmarking
8.1.14.4. Strategic Initiatives
Note: Product cover images may vary from those shown
3 of 4
  • IQVIA
  • PAREXEL International Corporation
  • Pharmaceutical Product Development, LLC
  • Charles River Laboratory
  • ICON Plc
  • Wuxi AppTec Inc
  • PRA Health Sciences
  • SGS SA
  • Syneos Health
  • Chiltern International Ltd
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer
  • Clinipace
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll